- Home
- ORKT vs INTS Comparison
ORKT vs INTS Comparison
Compare ORKT & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORKT
- INTS
- Stock Information
- Founded
- ORKT 2003
- INTS 2012
- Country
- ORKT Singapore
- INTS United States
- Employees
- ORKT N/A
- INTS N/A
- Industry
- ORKT
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- ORKT
- INTS Health Care
- Exchange
- ORKT NYSE
- INTS Nasdaq
- Market Cap
- ORKT N/A
- INTS 9.4M
- IPO Year
- ORKT 2024
- INTS 2023
- Fundamental
- Price
- ORKT $0.53
- INTS $0.32
- Analyst Decision
- ORKT Strong Buy
- INTS Strong Buy
- Analyst Count
- ORKT 1
- INTS 3
- Target Price
- ORKT $5.00
- INTS $8.50
- AVG Volume (30 Days)
- ORKT 227.2K
- INTS 2.6M
- Earning Date
- ORKT 01-01-0001
- INTS 08-07-2025
- Dividend Yield
- ORKT N/A
- INTS N/A
- EPS Growth
- ORKT N/A
- INTS N/A
- EPS
- ORKT N/A
- INTS N/A
- Revenue
- ORKT $2,962,282.00
- INTS N/A
- Revenue This Year
- ORKT $9.63
- INTS N/A
- Revenue Next Year
- ORKT N/A
- INTS N/A
- P/E Ratio
- ORKT N/A
- INTS N/A
- Revenue Growth
- ORKT N/A
- INTS N/A
- 52 Week Low
- ORKT $0.40
- INTS $0.26
- 52 Week High
- ORKT $8.00
- INTS $5.10
- Technical
- Relative Strength Index (RSI)
- ORKT N/A
- INTS 37.08
- Support Level
- ORKT N/A
- INTS $0.28
- Resistance Level
- ORKT N/A
- INTS $0.32
- Average True Range (ATR)
- ORKT 0.00
- INTS 0.06
- MACD
- ORKT 0.00
- INTS 0.01
- Stochastic Oscillator
- ORKT 0.00
- INTS 7.43
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.